MXPA04003732A - Metodos y composiciones para inducir la citotoxicidad especifica de los tumores. - Google Patents

Metodos y composiciones para inducir la citotoxicidad especifica de los tumores.

Info

Publication number
MXPA04003732A
MXPA04003732A MXPA04003732A MXPA04003732A MXPA04003732A MX PA04003732 A MXPA04003732 A MX PA04003732A MX PA04003732 A MXPA04003732 A MX PA04003732A MX PA04003732 A MXPA04003732 A MX PA04003732A MX PA04003732 A MXPA04003732 A MX PA04003732A
Authority
MX
Mexico
Prior art keywords
methods
compositions
vectors
specific cytotoxicity
inducing tumor
Prior art date
Application number
MXPA04003732A
Other languages
English (en)
Inventor
Ayesh Suhail
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of MXPA04003732A publication Critical patent/MXPA04003732A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se refiere a la replicacion y/o expresion viral especifica del tumor que usa vectores virales replicativos de manera condicional, en que la expresion de un producto de gen esencial para la replicacion viral se controla por una secuencia reguladora H19. Esta invencion proporciona tales vectores virales, los metodos para preparar tales vectores y los metodos para administrar tales vectores. Las composiciones y metodos de la invencion son utiles en el tratamiento del cancer y los desordenes hiperproliferativos.
MXPA04003732A 2001-10-22 2002-10-22 Metodos y composiciones para inducir la citotoxicidad especifica de los tumores. MXPA04003732A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/012,131 US7041654B2 (en) 1997-10-03 2001-10-22 Methods and compositions for inducing tumor-specific cytotoxicity
PCT/IL2002/000843 WO2003035883A2 (en) 2001-10-22 2002-10-22 Methods and compositions for inducing tumor-specific cytotoxicity

Publications (1)

Publication Number Publication Date
MXPA04003732A true MXPA04003732A (es) 2004-07-23

Family

ID=21753530

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003732A MXPA04003732A (es) 2001-10-22 2002-10-22 Metodos y composiciones para inducir la citotoxicidad especifica de los tumores.

Country Status (8)

Country Link
US (1) US7041654B2 (es)
EP (1) EP1438412A2 (es)
JP (1) JP2005506386A (es)
CN (1) CN1608135A (es)
CA (1) CA2464394A1 (es)
IL (1) IL161553A0 (es)
MX (1) MXPA04003732A (es)
WO (1) WO2003035883A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005292033A1 (en) * 2004-09-30 2006-04-13 Ariad Pharmaceuticals, Inc. Treatment method
NZ577283A (en) * 2005-03-07 2010-11-26 Robarts Res Inst Use of a Myxoma virus that does not express functional M135R
AU2006267841B2 (en) * 2005-07-07 2011-12-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating H19, and methods of using same
CA2675967A1 (en) * 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusale M Nucleic acid constructs and methods for specific silencing of h19
US20100196403A1 (en) * 2007-01-29 2010-08-05 Jacob Hochman Antibody conjugates for circumventing multi-drug resistance
RU2487165C2 (ru) * 2007-10-25 2013-07-10 Йиссум Ресерч Девелопмент Компани оф де Хебрю Юниверсити оф Джерусалем Лтд. Конструкции, содержащие составные экспрессионные кассеты, для терапии рака
US8188252B2 (en) * 2008-11-17 2012-05-29 University Of Rochester Rad51 derived cancer cell specific promoters for targeted anti-cancer therapy
EP2379720B1 (en) 2009-01-20 2016-08-17 Alona Zilberberg Mir-21 promoter driven targeted cancer therapy
US9018182B2 (en) * 2010-04-26 2015-04-28 Green Cross Corporation Tumor specific promoter and oncolytic virus vector comprising the same
US10987432B2 (en) * 2013-09-05 2021-04-27 The University Of Hong Kong Therapeutic delivery and expression system, methods and uses thereof
CN107249579A (zh) * 2014-12-03 2017-10-13 韦恩州立大学 涉及增生性疾病的组合物和方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699191B1 (fr) 1992-12-16 1995-02-10 Univ Paris Curie Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs.
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
FR2712602B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
IL108879A (en) 1994-03-07 2000-08-31 Yissum Res Dev Co Diagnostic assay for malignancies using the H19 gene and kit
FR2723697B1 (fr) 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
FR2725213B1 (fr) 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6087164A (en) 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
AU1190901A (en) 1999-09-30 2001-04-30 Trustees Of The University Of Pennsylvania, The Replication selective adenoviruses for use in cancer therapy

Also Published As

Publication number Publication date
EP1438412A2 (en) 2004-07-21
CN1608135A (zh) 2005-04-20
US20040082529A1 (en) 2004-04-29
IL161553A0 (en) 2004-09-27
JP2005506386A (ja) 2005-03-03
CA2464394A1 (en) 2003-05-01
US7041654B2 (en) 2006-05-09
WO2003035883A3 (en) 2003-11-27
WO2003035883A2 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
MXPA04003732A (es) Metodos y composiciones para inducir la citotoxicidad especifica de los tumores.
WO2005018555A3 (en) Lipid-modified immune response modifiers
MX2019001920A (es) Arn la terapia contra el cancer.
MXPA06000619A (es) Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
SG149829A1 (en) Pyrazolopyridines and analogs thereof
DE60130799D1 (en) Synthese von 4-aminothalidomid enantiomeren
PL398576A1 (pl) Preparaty szczepionek, preparaty farmaceutyczne, atenuowany wirus grypy, sposoby szczepienia, sposoby zapobiegania chorobie zakaznej, sposoby leczenia lub profilaktyki nowotworów, kompozycje szczepionek i kompozycje farmaceutyczne
MY145983A (en) Aryloxy and arylalkyleneoxy substituted imidazoquinolines
WO2004014953A3 (en) Anti-myelin associated glycoprotein (mag) antibodies
HUP0003745A2 (hu) Eljárások és készítmények tumorspecifikus citotoxicitás indukálására
PL372294A1 (en) Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
WO2003030934A3 (en) Cpg formulations and related methods
IL101963A0 (en) Isolated and purified dna sequences coding antigen expressed by tumor cells and recognized by cytotoxic t cells,and uses thereof
HUP0401534A2 (hu) Módosított humán IX. faktor
HU9401444D0 (en) Urethanes and ureas that induce cytokine production
MY129376A (en) Novel pharmaceutical formulations of modafinil
MY137435A (en) Retinoid compounds (i)
EP1461313A4 (en) INHIBITORS OF HUMAN ADAM-10
AU688101B2 (en) Live vaccine for the treatment of tumour diseases
TW200510449A (en) Acylated nonadepsipeptides
WO2002024897A3 (en) Conditionally replicating viral vectors and their use
WO2005017130A3 (en) Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof
HK1074643A1 (en) Recombinant mva capable of expressing structural hcv antigens
HUP0303450A2 (hu) Eljárás metoprololt tartalmazó mikrorészecskék előállítására és ezeket tartalmazó gyógyszerkészítmények
EP1070122A4 (en) INDUCTION OF THE EXPRESSION OF APOPTOTIC OR CYTOTOXIC GENES BY CO-SUPPORT OF ADENOVIRAL MEDIATED GENES